You are here: Industry Insights > Roche

News List

Roche lines up Bavarian Nordic vaccine for Tecentriq combo test in bladder cancer fiercepharma
March 16, 2017
Combinations are where it's at in immuno-oncology these days, and Merck & Co. and Bristol-Myers Squibb have each paired their PD-1 meds with cancer vaccines from smaller players. Now, third-to-the-field Roche is following that strategy with its own offeri
SMC welcomes Roche’s Gazyvaro but rejects Shire’s Onivyde pharmatimes
March 15, 2017
Patients with follicular lymphoma in Scotland have gained a new treatment option for the condition after the Scottish Medicines Consortium (SMC) published advice accepting Roche’s Gazyvaro for routine use by NHS Scotland.
Roche Annual General Meeting 2017 worldpharmanews
March 15, 2017
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its shareholders approved all proposals of the Board of Directors at its ordinary Annual General Meeting (AGM).
Roche reaches global settlement, licensing agreements with Mylan on Herceptin biosimilar firstwordpharma
March 14, 2017
Mylan announced Monday that it agreed to the terms of a settlement with Roche and the Swiss drugmaker's Genentech unit in regards to patents for Herceptin (trastuzumab).
Phase III APHINITY study shows Roche's Perjeta® regimen helped people with an aggressive type of ear worldpharmanews
March 07, 2017
Roche (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and Frontier Science Foundation (FS) have announced positive results from the phase III APHINITY study.
Combination of Roche's Perjeta, Herceptin cuts disease recurrence, death in breast cancer study firstwordpharma
March 03, 2017
Roche announced Thursday that the Phase III APHINITY study met its primary endpoint, showing that adjuvant treatment with the combination of Perjeta (pertuzumab)...
AC Immune says partner Roche to start second late-stage study of Alzheimer's disease drug crenezumab firstwordpharma
March 01, 2017
Roche's partner AC Immune said Tuesday that the former has decided to initiate a second Phase III study of the experimental Alzheimer's disease therapy crenezumab. AC Immune noted that the CREAD2 trial will enrol 750 patients with prodromal or mild Alzhei
EU nod for Roche’s lung cancer drug Alecensa pharmatimes
February 23, 2017
European regulators have given the go-ahead to Roche's Alecensa as a treatment for people with previously treated ALK-positive non-small cell lung cancer (NSCLC).
Roche and Discuva extend agreement to develop target antimicrobials pharmafile
February 23, 2017
Discuva, a drug discovery company based in Cambridge, UK, has announced that its collaboration with Roche, first agreed in 2014, has been extended until February 2018.
Patheon acquires Roche’s manufacturing facility in South Carolina, US pharmaceutical-technology
February 06, 2017
Drug development and delivery solutions provider Patheon has completed the acquisition of a manufacturing facility from Roche in Florence, South Carolina, US.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 45 46 Next page